<ol>
<li><strong>Amoebic Liver Access</strong></li>
</ol>
<p>Amoebic liver abscess is a collection of typically brownish coloured fluid in the liver, occurring often as a single mass in the right lobe and a complication of intestinal infection with Entamoeba histolytica. Lung, heart and brain infections are uncommon sequelae. Occasionally, pyogenic abscesses may have a similar clinical presentation.</p>
<p>Treatment of amoebic abscesses should be initiated with a tissue agent active against the trophozoite form followed by a luminal agent to eliminate intra-luminal cysts.</p>
<p><strong>CAUSES</strong></p>
<ul>
<li><em>Entamoeba histolytica</em></li>
</ul>
<p><strong>SYMPTOMS</strong></p>
<ul>
<li>Right upper abdominal pain referable to the epigastrium, right chest or right shoulder</li>
<li>Fever</li>
<li>Malaise</li>
<li>Sweats</li>
<li>Cough</li>
<li>Hiccups</li>
<li>Anorexia</li>
<li>Weight loss</li>
<li>Jaundice (uncommon)</li>
<li>Concurrent diarrhoea (less than one-third of patients)</li>
</ul>
<p><strong>SIGNS</strong></p>
<ul>
<li>Large tender liver</li>
<li>Tenderness and/or bulging at right intercostal spaces</li>
<li>Jaundice</li>
<li>Dullness to percussion on the right lower chest zones with basal crepitations</li>
<li>Amoebic empyema following extension into the chest cavity</li>
<li>Peritonitis (uncommon)</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<ul>
<li>Abdominal ultrasound</li>
<li>Chest X-ray</li>
<li>FBC</li>
<li>ESR</li>
<li>Stool examination</li>
<li>Abdominal CT scan</li>
<li>Serology (amoebic antibodies)</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives</strong></p>
<ul>
<li>To eradicate Entamoeba histolytica infection</li>
<li>To prevent further destruction of liver tissue</li>
<li>To prevent further complications (e.g. rupture of abscess into pleural, pericardial or peritoneal space)</li>
</ul>
<p><strong>Non-pharmacological treatment</strong></p>
<ul>
<li>Therapeutic aspiration may be required in patients with poor</li>
</ul>
<p>response to therapy</p>
<p><strong>Pharmacological treatment</strong></p>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Metronidazole, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>800 mg 8 hourly for 10 days (tissue agent)</p>
<p><u>Children</u></p>
<p>15 mg/kg 8 hourly for 10 days (tissue agent)</p>
<p><strong>Then</strong></p>
<ul>
<li>Diloxanide furoate, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>500 mg 8 hourly for 10 days (luminal agent)</p>
<p><u>Children</u></p>
<p>6-8 mg/kg 8 hourly for 10 days (luminal agent)</p>
<p>2nd Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Tinidazole, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>2 g once daily for 5 days (tissue agent)</p>
<p><u>Children</u></p>
<p>&gt;3 years; 50 mg/kg (max. 2 g) once daily for 5 days (tissue agent)</p>
<p><strong>Then</strong></p>
<ul>
<li>Paromomycin, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>8-10 mg/kg 8 hourly for 7 days (luminal agent)</p>
<p><u>Children</u></p>
<p>8-10 mg/kg 8 hourly for 7 days (luminal agent)</p>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>&nbsp;Patients with abscesses that are large or not responding to treatment will need to be referred to a specialist.</p>
<ol>
<li><strong>9</strong><strong>.</strong><strong> Jaundice</strong></li>
</ol>
<p>Jaundice refers to yellow pigmentation of skin, palms and the sclerae as a result of elevated levels of bilirubin in blood. It may be visible when serum levels exceed 35 micromol/L in adults and 100 micromol/L in children. The symptoms and signs that accompany jaundice often provide helpful clues to the underlying cause.</p>
<p>In adults and children, hyperbilirubinaemia may result in hepatic encephalopathy (See sections on 'Acute and Chronic Hepatitis' and 'Hepatic Encephalopathy'). Jaundice in neonates can result in kernicterus (bilirubin encephalopathy) because of the consequences of hyperbilirubinaemia on the brain of the newborn. (See section on 'Neonatal Jaundice')</p>
<p><strong>CAUSES</strong></p>
<p><strong>Adults</strong></p>
<ul>
<li>Hepatitis - viral, alcoholic, drug-induced including allopathic and herbal preparations</li>
<li>Haemolysis - various causes including malaria, Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and sickle cell disease, allopathic drugs and herbal preparations</li>
<li>Chronic liver diseases - decompensated cirrhosis, biliary cirrhosis, chronic hepatitis, hepatocellular carcinoma</li>
<li>Liver malignancies - hepatocellular carcinoma, metastatic liver disease</li>
<li>Hepatic congestion from heart failure</li>
<li>Gall bladder diseases - stones, infections</li>
<li>Carcinoma of head of pancreas</li>
<li>Septicaemia</li>
</ul>
<p><strong>Children</strong></p>
<ul>
<li>Haemolysis - sickle cell disease, G6PD deficiency, drugs</li>
<li>Infections - malaria, hepatitis, urinary tract infections, typhoid fever and other septicaemic illnesses</li>
</ul>
<p><strong>Pregnancy</strong></p>
<p>(See section on 'Jaundice in Pregnancy')</p>
<p><strong>Neonates</strong></p>
<p>(See section on 'Neonatal Jaundice')</p>
<p><strong>SYMPTOMS</strong></p>
<ul>
<li>Yellow or greenish discolouration of the eyes or skin</li>
<li>Deep yellow discolouration of urine</li>
<li>Itching</li>
<li>Pale stools</li>
</ul>
<p><strong>SIGNS</strong></p>
<ul>
<li>Pallor (may indicate haemolysis, chronic disease or malignancy)</li>
<li>Scratch marks (indicative of cholestasis)</li>
<li>Stigmata of chronic liver disease (e.g. palmar erythema, clubbing, spider naevi)</li>
<li>Hepatomegaly (may be tender)</li>
<li>Splenomegaly in portal hypertension</li>
<li>Palpable gall bladder</li>
<li>Ascites</li>
<li>Bleeding (cephalhaematoma subgaleal, haematoma, upper gastrointestinal bleeding)</li>
<li>Hepatic flap (indicative of liver failure)</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<p><strong>Adults and children</strong></p>
<ul>
<li>FBC</li>
<li>INR</li>
<li>Sickling status</li>
<li>G6PD status</li>
<li>Blood film for red cell anomalies, malaria parasites</li>
<li>Liver function tests</li>
<li>Urea and electrolytes</li>
<li>Hepatitis screen (HBsAg, HCV Antibody, Hepatitis A IgM, Hepatitis E IgM)</li>
<li>Blood culture</li>
<li>Urinalysis</li>
<li>Abdominal ultrasound</li>
<li>Abdominal CT scan</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives</strong></p>
<ul>
<li>To identify and treat cause of jaundice</li>
<li>To relieve symptoms associated with jaundice</li>
<li>To prevent complications associated with elevated levels of bilirubin</li>
</ul>
<p>in the blood</p>
<p><strong>Non-pharmacological treatment</strong></p>
<p><strong>Adults and children</strong></p>
<p>(See section on 'Hepatic encephalopathy', Hepatitis')</p>
<ul>
<li>Avoid alcohol and other hepatotoxic agents</li>
<li>Ensure adequate hydration</li>
</ul>
<p><strong>Pharmacological treatment</strong></p>
<ol>
<li><strong> Cholestatic jaundice with severe pruritus while investigating for underlying aetiology</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Cholestyramine, oral,</li>
</ul>
<p><u>Adult</u></p>
<p>4 g 12 hourly (titrate dose to response and tolerance: max. 16 g/day)</p>
<p><u>Children</u> and <u>Adolescents</u></p>
<p>2-4 g 12 hourly (max. 8 g/day)</p>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>Refer patients with unexplained jaundice to a specialist for further evaluation and management.</p>
<ol>
<li><strong> Acute Hepatitis</strong></li>
</ol>
<p>Hepatitis is defined as inflammation of the liver and has multiple causes. It may present as an acute illness with jaundice and altered liver function tests. When symptoms, signs or laboratory abnormalities persist for more than 6 months it is considered chronic.</p>
<p><strong>CAUSES</strong></p>
<ul>
<li>Viruses (Hepatitis A, B, C, D and E, Yellow Fever etc.)</li>
<li>Drugs (allopathic, alternative and herbal preparations)</li>
<li>Alcohol</li>
<li>Autoimmune</li>
</ul>
<p><strong>SYMPTOMS</strong></p>
<ul>
<li>Right hypochondrial pain</li>
<li>Fever (occurring 1 to 4 weeks before the jaundice appears)</li>
<li>Malaise</li>
<li>Anorexia</li>
<li>Nausea</li>
<li>Vomiting</li>
<li>Yellow or dark coloured urine</li>
<li>Pale stools</li>
<li>Itching</li>
<li>Fatigue</li>
<li>Confusion</li>
</ul>
<p><strong>SIGNS</strong></p>
<ul>
<li>Jaundice</li>
<li>Right hypochondrial tenderness</li>
<li>Hepatomegaly</li>
<li>Asterixis</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<ul>
<li>FBC</li>
<li>Liver function tests</li>
<li>Hepatitis screen (HBsAg, HCV Antibody, Hepatitis A IgM, Hepatitis E IgM)</li>
<li>Antinuclear Antibody, Anti-smooth muscle Antibody</li>
<li>Abdominal Ultrasound</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives</strong></p>
<ul>
<li>To identify and eliminate the precipitating cause</li>
<li>To relieve symptoms</li>
</ul>
<p><strong>Non-pharmacological treatment</strong></p>
<ul>
<li>Rest</li>
<li>High calorie fluids (especially glucose drinks, fruit juice, light porridge, koko, rice-water, mashed kenkey)</li>
<li>Intravenous fluids if volume deplete</li>
<li>Any food that the patient can tolerate</li>
<li>Avoid alcohol</li>
</ul>
<p><strong>Pharmacological treatment</strong></p>
<ul>
<li>Supportive care (analgesia, fluid replacement, etc. as required)</li>
</ul>
<p><strong>Note 2-1:</strong></p>
<p>Avoid hepatotoxic drugs such as paracetamol and high doses of anxiolytic-hypnotics.</p>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>Refer patients with rapidly progressing symptoms and signs to a physician specialist.</p>
<ol>
<li><strong>11</strong><strong>.</strong><strong> Chronic Hepatitis</strong></li>
</ol>
<p>This refers to chronic inflammation of the liver of more than 6 months duration, with persistently elevated liver function tests. Chronic hepatitis can progress to liver cirrhosis, portal hypertension with upper gastrointestinal bleeding, hepatic encephalopathy and hepatocellular carcinoma.</p>
<p>Immunisation against Hepatitis B is now available for children under the Expanded Programme on Immunisation (EPI). Adults in endemic areas including Ghana should be immunised against Hepatitis B infection after initial assessment of their immunological status regarding previous exposure to the virus.</p>
<p>Long-term monitoring for disease activity and hepatocellular carcinoma screening with six-monthly Hepatitis B viral DNA quantification, LFTs, abdominal ultrasound and alpha fetoprotein is mandatory for patients with chronic hepatitis B.</p>
<p><strong>CAUSES</strong></p>
<ul>
<li>Hepatitis B virus (HBV)</li>
<li>Hepatitis C virus (HCV)</li>
<li>Hepatitis E virus (genotype 3)</li>
</ul>
<p><strong>SYMPTOMS</strong></p>
<ul>
<li>Usually asymptomatic</li>
<li>Mild non-specific symptoms</li>
<li>Recurrent fever</li>
<li>Arthralgia</li>
<li>Malaise</li>
<li>Jaundice</li>
<li>Lethargy</li>
</ul>
<p><strong>SIGNS</strong></p>
<p><strong>Stigmata of chronic liver disease</strong></p>
<ul>
<li>Palmar erythema</li>
<li>Clubbing</li>
<li>Dupuytren's contracture</li>
<li>Parotid enlargement</li>
<li>Gynaecomastia</li>
<li>Testicular atrophy</li>
<li>Spider naevi</li>
</ul>
<p><strong>Signs of decompensated liver disease</strong></p>
<ul>
<li>Jaundice</li>
<li>Ascites</li>
<li>Encephalopathy</li>
<li>Peripheral oedema (hypoalbuminaemia)</li>
<li>Purpura/skin bruising (coagulopathy)</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<ul>
<li>FBC</li>
<li>LFTs</li>
<li>INR</li>
<li>HIV</li>
<li>Baseline Alpha-Feto-protein</li>
<li>Abdominal ultrasound scan</li>
<li>Liver biopsy</li>
</ul>
<p><strong>Chronic Hepatitis B</strong></p>
<ul>
<li>Hepatitis B surface Antigen (HBsAg)</li>
<li>HBc IgG</li>
<li>Hepatitis-B-e-antigen (HBeAg) &amp; Anti-HBe</li>
<li>Hepatitis B Viral Load</li>
</ul>
<p><strong>Chronic Hepatitis C</strong></p>
<ul>
<li>Hepatitis C Virus (HCV) antibody testing</li>
<li>HCV RNA</li>
<li>HCV genotyping</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives</strong></p>
<ul>
<li>To prevent disease progression and complications</li>
<li>To prevent hepatic encephalopathy</li>
<li>To improve synthetic liver function through viral suppression</li>
<li>To prevent transmission</li>
</ul>
<p><strong>Non-pharmacological treatment</strong></p>
<ul>
<li>Prevention of transmission to partners (e.g. protected sex, not sharing of toothbrushes and sharps, blades, needles, body piercings, tattoos, cultural scarification practices, circumcisions etc.)</li>
<li>Lifestyle/dietary advice</li>
<li>Spouse/household screening</li>
</ul>
<p><strong>Pharmacological treatment</strong></p>
<ol>
<li><strong> Chronic Active Hepatitis B (HBeAg positive or HBeAg negative)</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Pegylated Interferon alfa-2a, subcutaneous,</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Tenofovir, oral,</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Entecavir, oral,</li>
</ul>
<p>2nd Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Lamivudine, oral,</li>
</ul>
<ol>
<li><strong>B</strong><strong>.</strong><strong> Decompensated liver cirrhosis/ Fulminant Liver failure from</strong></li>
</ol>
<p><strong>Chronic Hepatitis B</strong></p>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Tenofovir, oral,</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Entecavir, oral,</li>
</ul>
<p>2nd Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Lamivudine, oral,</li>
</ul>
<ol>
<li><strong> Patients with Chronic Hepatitis B undergoing chemotherapy or immunosuppressive treatment</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Tenofovir, oral,</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Entecavir, oral,</li>
</ul>
<p>2nd Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Lamivudine, oral,</li>
</ul>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>&nbsp;Refer all cases of chronic hepatitis B infection to a specialist, especially those who have failed first-line anti-viral therapy or had adverse reactions to anti-viral therapy or have liver-related complications (e.g. liver cirrhosis, liver failure, liver mass, signs of portal hypertension, ascites, peripheral oedema, hypoalbuminaemia). Pregnant individuals and patients with hepatitis B co-infections (e.g. HIV/Hepatitis C) as well as those requiring chemotherapy or other immunosuppressive therapy should also be referred to a specialist.</p>
<p><strong>Post-exposure management of healthcare workers after occupational exposure to Hepatitis B infection</strong></p>
<table>
<tbody>
<tr>
<td>
<p><strong>Table 2-1: Post-exposure management of healthcare workers after occupational exposure to Hepatitis B infection</strong></p>
</td>
</tr>
<tr>
<td>
<p>*HCW Status</p>
</td>
<td>
<p>Post-Exposure Testing</p>
</td>
<td>
<p>Post-Exposure Prophylaxis</p>
</td>
<td>
<p>Post-Vac- cination Anti-HBs</p>
</td>
</tr>
<tr>
<td>
<p>Source</p>
<p>Patient</p>
</td>
<td>
<p>*HCW</p>
<p>Anti-HBs</p>
</td>
<td>
<p>&sect;HBIG</p>
</td>
<td>
<p>HBV</p>
<p>Vaccination</p>
</td>
</tr>
<tr>
<td>
<p>Documented Responder (&gt; 3 Doses Received)</p>
</td>
<td>
<p>No action required</p>
</td>
</tr>
<tr>
<td>
<p>Documented Non- Responder (After &gt; 6 Doses)</p>
</td>
<td>
<p>Positive</p>
</td>
<td>
<p>-</p>
</td>
<td>
<p><sup>&sect;</sup>HBIG Twice (0ne Month Apart)</p>
</td>
<td>
<p>-</p>
</td>
<td>
<p>No</p>
</td>
</tr>
<tr>
<td>
<p>Negative</p>
</td>
<td>
<p>-</p>
</td>
<td>
<p>No Action Required</p>
</td>
</tr>
<tr>
<td>
<p>Response Unknown (After &gt;3 Doses)</p>
</td>
<td>
<p>Positive/ Unknown</p>
</td>
<td>
<p>&lt;10 MIU/ml</p>
</td>
<td>
<p><sup>&sect;</sup>HBIG 0nce</p>
</td>
<td>
<p>Revaccinate</p>
</td>
<td>
<p>Yes</p>
</td>
</tr>
<tr>
<td>
<p>Negative</p>
</td>
<td>
<p>&lt;10 MIU/ml</p>
</td>
<td>
<p>None</p>
</td>
<td>
<p>Revaccinate</p>
</td>
<td>
<p>Yes</p>
</td>
</tr>
<tr>
<td>
<p>Any Result</p>
</td>
<td>
<p>&gt;10 MIU/ml</p>
</td>
<td>
<p>No action required</p>
</td>
</tr>
<tr>
<td>
<p>Unvaccinated/ Incomplete Vaccination</p>
</td>
<td>
<p>Positive/ Unknown</p>
</td>
<td>
<p>-</p>
</td>
<td>
<p>HBIG once</p>
</td>
<td>
<p>Complete Vaccination</p>
</td>
<td>
<p>Yes</p>
</td>
</tr>
<tr>
<td>
<p>Negative</p>
</td>
<td>
<p>-</p>
</td>
<td>
<p>None</p>
</td>
<td>
<p>Complete Vaccination</p>
</td>
<td>
<p>Yes</p>
</td>
</tr>
</tbody>
</table>
<p>*HCW: Healthcare worker</p>
<p>HBIG: Hepatitis B Immunoglobulin as soon as possible when indicated (0.06 ml/kg IM)</p>
<p><strong>Note 2-2</strong></p>
<p>Anti-HBs Titre should be performed 1-2 months after last dose of HBV vaccina- tion series but ~ 4-6 months after HBIG to avoid detection of passively admin- istered Anti-HBs.</p>
<p>Responder: person with Anti-HBs &gt; 10 MIU/ml after 3 or more HBV vaccination doses.</p>
<p>Non-responder: person with Anti-HBs &lt; 10 MIU/ml after 6 or more HBV vaccination doses.</p>
<p><strong>Note 2-3</strong></p>
<p>All HCWS who have Anti-Hbs &lt; 10 MIU/ml, unvaccinated or incomplete vaccination and sustain exposure to a source patient who is HBsAg-positive/ unknown HBsAg status should undergo HBsAg screening as soon as possible after expo- sure and follow up testing ~ 6 months later (HBsAg + Anti-HBc).</p>
<ol>
<li><strong> Chronic Hepatitis C (Genotype 2 &amp; 3)</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Pegylated Interferon alfa-2a, subcutaneous,</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Pegylated Interferon alfa-2b, subcutaneous,</li>
</ul>
<p><strong>And</strong></p>
<ul>
<li>Ribavirin, oral,</li>
</ul>
<ol>
<li><strong> Chronic Hepatitis C (Genotype 1 &amp; 4)</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Pegylated Interferon alfa-2a, subcutaneous,</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Pegylated Interferon alfa-2b, subcutaneous,</li>
</ul>
<p><strong>And</strong></p>
<ul>
<li>Ribavirin, oral,</li>
</ul>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>Refer all cases of chronic hepatitis C infection to a specialist, especially those who have failed first-line anti-viral therapy or had adverse reactions to anti-viral therapy or have liver-related complications (e.g. liver cirrhosis, liver failure, liver mass, signs of portal hypertension, ascites, peripheral oedema, hypoalbuminaemia). Pregnant individuals and patients with hepatitis C co-infections (e.g. HIV/Hepatitis B) as well as those requiring chemotherapy or other immunosuppressive therapy should also be referred to a specialist.</p>
<ol>
<li><strong> Hepatic Encephalopathy</strong></li>
</ol>
<p>This condition is a complication of either acute or chronic liver disease. It presents with disordered central nervous system function, due to inability of the liver to detoxify ammonia and other chemicals.</p>
<p><strong>CAUSES</strong></p>
<ul>
<li>Viral hepatitis</li>
<li>Alcoholic hepatitis</li>
<li>Cirrhosis of the liver</li>
<li>Hepatocellular carcinoma</li>
<li>Drugs e.g. halothane, isoniazid, paracetamol overdose, herbal preparations</li>
<li>Fatty liver of pregnancy</li>
<li>Precipitating factors in a patient with pre-existing liver disease:</li>
<li>Fever</li>
<li>Hypotension</li>
<li>Infection</li>
<li>Fluid and electrolyte imbalance (excessive use of loop diuretics)</li>
<li>Sedatives</li>
<li>Increased gastrointestinal tract (GIT) protein load e.g. heavy GIT bleeding, alcoholic binge</li>
</ul>
<p><strong>SYMPTOMS</strong></p>
<ul>
<li>Jaundice</li>
<li>Confusion</li>
<li>Disturbed consciousness which progresses as follows: disorder of sleep, hypersomnia and inversion of sleep rhythm, apathy and eventually coma</li>
<li>Personality changes</li>
</ul>
<p><strong>SIGNS</strong></p>
<ul>
<li>Cyanosis</li>
<li>Fetor hepaticus</li>
<li>Signs of chronic liver disease</li>
<li>Neurological abnormalities:</li>
<li>Speech impairment</li>
<li>Asterixis (a flapping tremor) indicates pre-coma and strongly supports the diagnosis of encephalopathy</li>
<li>Inability to draw or construct objects e.g. a 5-pointed star</li>
<li>Incoordination</li>
<li>Lethargy</li>
<li>Encephalopathy
<ul>
<li>Grade 1: Mild confusion, irritable, tremor, restless</li>
<li>Grade 2: Lethargic responses, decreased inhibitions, disorientation, agitation, asterixis</li>
<li>Grade 3: Stuporous but arousable, aggressive bursts, inarticulate speech and marked confusion</li>
<li>Grade 4: Coma</li>
</ul>
</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<ul>
<li>FBC</li>
<li>Blood glucose</li>
<li>Liver function tests</li>
<li>Blood urea and electrolytes</li>
<li>Hepatitis B-surface-Antigen</li>
<li>Hepatitis C screen</li>
<li>Prothrombin time, INR</li>
<li>Infection screen (blood culture, urine RE, chest X-Ray, diagnostic ascitic tap)</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives</strong></p>
<ul>
<li>To identify and correct precipitating factors promptly</li>
<li>To treat underlying cause of liver disease</li>
</ul>
<p><strong>Non-pharmacological treatment</strong></p>
<ul>
<li>Place in the coma position if unconscious</li>
<li>Maintain fluid and electrolyte balance (avoid dehydration and</li>
</ul>
<p>electrolyte abnormalities such as hypokalaemia)</p>
<ul>
<li>Monitor temperature, pulse and respiratory rate, blood pressure, pupils, urine output and blood glucose regularly</li>
<li>Avoid alcohol, paracetamol and other hepatotoxic agents</li>
<li>Avoid sedatives such as benzodiazepines and drugs that impair the coagulation system</li>
<li>Patients should N0T have their protein intake restricted</li>
<li>Maintain an adequate protein intake of 1.2-1.5 g/kg per day</li>
<li>Encourage intake of high carbohydrate diet by mouth or NG tube</li>
</ul>
<p><strong>Pharmacological treatment</strong></p>
<ol>
<li><strong>Measures to correct hydration status and nutrition</strong></li>
</ol>
<p>Evidence Rating: [A]</p>
<p><u>Adults</u></p>
<ul>
<li>Dextrose saline (5-10% dextrose in 0.9% saline), IV, 500 ml 8 hourly (according to requirements)</li>
</ul>
<p><strong>And</strong></p>
<ul>
<li>High potency Vitamin B, IV, (formulated as two separate vials) 0ne pair of vials daily (added to glucose IV solution)</li>
</ul>
<p><u>Children</u></p>
<ul>
<li>Dextrose saline (4.3% in 0.18% saline), IV,</li>
</ul>
<p><strong>And</strong></p>
<ul>
<li>High potency Vitamin B, IV, (formulated as two separate vials)</li>
</ul>
<ol>
<li><strong> Measures to lower blood ammonia concentration</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Lactulose, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>Start with 30-45 ml (20-30 g), 6-12 hourly</p>
<p>(Review dose to maintain 2-3 semi-solid stools per day)</p>
<p><u>Children</u> and <u>Adolescents</u></p>
<p>Start with 5-20 ml 6-12 hourly</p>
<p>(Review dose to maintain 2-3 semi-solid stools per day)</p>
<p><u>Neonates</u></p>
<p>Start with 0.5-5 ml 6-12 hourly</p>
<p>(Review dose to maintain 2-3 semi-solid stools per day)</p>
<p><strong>Or</strong></p>
<ul>
<li>Lactulose, rectal,</li>
</ul>
<p>300 ml diluted in 700 ml water (via rectal balloon catheter) 4-6 hour- ly, retain in the rectum for 30-60 minutes. (Review dose to maintain 2-3 semi-solid stools per day)</p>
<p><strong>And</strong></p>
<ul>
<li>Metronidazole, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>400 mg 8 hourly</p>
<p><u>Children</u></p>
<p>15 mg/kg 12 hourly</p>
<p><u>Neonates</u></p>
<p>&gt;2 kg; 15 mg/kg 12 hourly</p>
<p>1-2 kg; 7.5 mg/kg 12 hourly</p>
<p>2nd Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Rifaximin, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>550 mg 12 hourly</p>
<p><u>Children</u></p>
<p>&gt;12 years; 200 mg 8 hourly</p>
<p>&lt; 12 years; not recommended</p>
<ol>
<li><strong> Hepatic encephalopathy associated with active bleeding (INR &gt; 1</strong><strong>.</strong><strong>5 or platelet count &lt; 50 x 109 /L)</strong></li>
</ol>
<p><u>Adults and Children (liaise with Haematology)</u></p>
<ul>
<li>Fresh frozen plasma, IV, (for INR &gt;1.5)</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Platelet concentrate, IV, (platelet count &lt; 50 x 109 /L)</li>
</ul>
<ol>
<li><strong> Antibiotic prophylaxis in Hepatic encephalopathy (associated with cirrhosis and upper gastro-intestinal haemorrhage)</strong></li>
</ol>
<p>Patients in whom oral administration is not possible,</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Ciprofloxacin, IV,</li>
</ul>
<p><u>Adults</u></p>
<p>400 mg 8-12 hourly (administered over 60 minutes)</p>
<p><strong>Or</strong></p>
<ul>
<li>Ceftriaxone, IV, 1 g daily for 7 days</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Ciprofloxacin, oral, 500 mg 12 hourly</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Norfloxacin, oral, 400 mg 12 hourly for 7 days</li>
</ul>
<ol>
<li><strong> Hepatic encephalopathy precipitated by bacterial infection</strong></li>
</ol>
<p><strong>Note 2-4</strong></p>
<p>A diagnosis of SBP is established if the neutrophil count in the ascitic fluid is &gt;250 cells/mL, culture results positive and surgically treatable causes are excluded. Patients with suspected SBP should be started on empiric antibiotics immediately after ascitic fluid is obtained pending results:</p>
<p>Evidence Rating: [A]</p>
<p>1st Line treatment</p>
<ul>
<li>Ciprofloxacin, IV, 400 mg 8-12 hourly for 2 days (to be administered over 60 minutes)</li>
</ul>
<p><strong>Then</strong></p>
<ul>
<li>Ciprofloxacin, oral, 500 mg 12 hourly for 5 days</li>
</ul>
<p><strong>Note 2-5</strong></p>
<p>Avoid in patients with prior fluoroquinolone therapy as SBP prophylaxis or his- tory of resistance<strong>.</strong></p>
<p>2nd Line treatment</p>
<ul>
<li>Cefotaxime, IV, 2 g 8 hourly for 7 days Or</li>
<li>Ceftriaxone, IV, 2 g daily for 7 days</li>
</ul>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>Refer patients if the condition does not improve. All children with hepatic encephalopathy must be referred to a specialist.</p>
<ol>
<li><strong>13</strong><strong>.</strong><strong> Ascites</strong></li>
</ol>
<p>Ascites is the accumulation of excess fluid within the peritoneal cavity.</p>
<p><strong>CAUSES</strong></p>
<ul>
<li>Portal hypertension secondary to liver cirrhosis</li>
<li>Renal failure</li>
<li>Nephrotic syndrome</li>
<li>Cardiac failure</li>
<li>Abdominal tuberculosis</li>
<li>Intra-abdominal or pelvic malignancies</li>
</ul>
<p><strong>SYMPTOMS</strong></p>
<ul>
<li>Abdominal enlargement</li>
<li>Abdominal discomfort or pain</li>
<li>Difficulty breathing</li>
</ul>
<p><strong>SIGNS</strong></p>
<ul>
<li>Distended abdomen</li>
<li>Shifting dullness</li>
<li>Fluid thrill</li>
<li>Abdominal tenderness</li>
<li>Signs relating to the underlying causes (See appropriate section)</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<ul>
<li>FBC</li>
<li>BUE &amp; Creatinine</li>
<li>LFTs</li>
<li>INR</li>
<li>Urinalysis</li>
<li>Abdomino-pelvic ultrasound</li>
<li>Chest X-ray</li>
<li>Diagnostic paracentesis</li>
<li>Appearance and colour</li>
<li>Gram stain</li>
<li>Cell count and differential</li>
<li>Biochemistry e.g. Albumin</li>
<li>Microscopy, culture (with bedside inoculation of aerobic &amp; an- aerobic blood culture bottles)</li>
<li>Acid fast bacilli</li>
<li>Cytology</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives</strong></p>
<ul>
<li>To relieve symptoms</li>
<li>To identify and manage underlying cause</li>
</ul>
<p><strong>Non-pharmacological treatment</strong></p>
<ul>
<li>Bed rest</li>
<li>Salt restriction &lt;2 g/day</li>
<li>Fluid restriction to &lt;1.5 L/day</li>
<li>Avoid NSAID-use</li>
<li>Alcohol abstinence</li>
<li>Therapeutic paracentesis (sterile abdominal tap) if ascites is tense</li>
</ul>
<p>and/or there is respiratory embarrassment</p>
<p><strong>Note 2-6</strong></p>
<p>Removal of up to 5 litres of ascitic fluid without concomitant colloid infusion is a safe short-term option and unlikely to have haemodynamic consequences.</p>
<p><strong>Pharmacological treatment</strong></p>
<ol>
<li><strong> Control of ascitic fluid accumulation</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Spironolactone, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>50-200 mg daily</p>
<p>0.3-3 mg/kg daily</p>
<p><strong>And</strong></p>
<ul>
<li>Furosemide, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>20-80 mg daily</p>
<p><u>Children</u></p>
<p>1-2 mg/kg daily</p>
<ol>
<li><strong>B</strong><strong>.</strong><strong> Massive ascites in liver cirrhosis with respiratory embarrassment</strong></li>
</ol>
<p><strong>requiring more than 5 litres of fluid drainage</strong></p>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>Salt-poor human albumin solution, IV, 6-8 g per litre of ascitic fluid drained</li>
</ul>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>Patients with the following conditions must be referred to a specialist. Poor response to diuretic therapy or diuretic-refractory ascites, complicated cirrhotic ascites with suspected spontaneous bacterial peritonitis, hepato-renal syndrome, and hepatic encephalopathy.</p>
<p>Also refer when an underlying cause cannot be identified.</p>
<ol>
<li><strong> Vomiting</strong></li>
</ol>
<p>Vomiting can be induced by a variety of disease processes including gastrointestinal, neurologic, renal, psychiatric, cardiovascular, endocrine, pain and the effects of drugs. The best course of action in identifying the underlying cause is to carry out a detailed clinical evaluation and management plan, looking out for the aetiology, consequences and potential complications of vomiting.</p>
<p>Severe uncontrolled vomiting can result in significant dehydration and electrolyte imbalance accompanied by renal complications.</p>
<p>Anti-emetics should be prescribed only when the cause of vomiting is known as they may delay diagnosis.</p>
<p><strong>CAUSES</strong></p>
<ul>
<li>Disorders of the gastro-intestinal tract (GIT) and liver: intestinal obstruction, peptic ulcer, pancreatitis, cholecystitis, gastroenteritis, hepatitis</li>
<li>Neurological disorders: severe pain, migraine, raised intracranial pressure (i.e. tumours, haemorrhage; meningitis); seizures, stroke</li>
<li>Endocrine and metabolic: diabetic ketoacidosis, uraemia, hypercalcaemia, intestinal pseudo-obstruction</li>
<li>Psychiatric: anxiety, depression, severe emotional upset, psychogenic vomiting</li>
<li>Drugs: cancer chemotherapy, aspirin, allopurinol, digoxin, erythromycin, anticonvulsants, opioids</li>
<li>Infections: malaria, urinary tract infections</li>
<li>Cardiovascular: acute myocardial infarction</li>
<li>Renal: uraemia from acute or chronic kidney disease</li>
<li>Miscellaneous: pregnancy, cyclical vomiting syndrome, myocardial infarction, labyrinthitis, otitis media</li>
</ul>
<p><strong>SYMPTOMS</strong></p>
<p><strong>Vomiting may be associated with:</strong></p>
<ul>
<li>Abdominal pain</li>
<li>Diarrhoea: gastroenteritis</li>
<li>Abdominal distension: suspected bowel obstruction</li>
<li>Heartburn: suspected gastro-oesophageal reflux disease</li>
<li>Chest pain</li>
<li>Jaundice: hepato-biliary disease</li>
<li>Vertigo and nystagmus: suspected vestibular neuronitis</li>
<li>Anxiety</li>
<li>Depression</li>
</ul>
<p><strong>Vomiting may have diagnostic clues e.g.:</strong></p>
<ul>
<li>Vomiting of food eaten several hours earlier: gastroparesis or gastric- outlet obstruction</li>
<li>Vomiting with blood: oesophageal, gastric or duodenal lesion</li>
<li>Early morning vomiting: pregnancy</li>
<li>Faeculent vomiting: intestinal obstruction, gastro-colic fistula</li>
<li>Projectile: if pyloric stenosis</li>
</ul>
<p><strong>SIGNS</strong></p>
<ul>
<li>Abdominal tenderness</li>
<li>Dehydration (reduced skin turgor, dry tongue, hypotension, tachycardia)</li>
<li>Abdominal distension</li>
<li>Succussion splash</li>
<li>Jaundice</li>
<li>Signs of peritonitis (rebound tenderness, rigidity, guarding)</li>
<li>Miscellaneous: e.g. vertigo, nystagmus, focal neurological signs, Kussmaul breathing (uraemia, diabetic ketoacidosis)</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<ul>
<li>FBC</li>
<li>BUE and Creatinine</li>
<li>LFT</li>
<li>Blood glucose</li>
<li>Serum amylase</li>
<li>Urine RE</li>
<li>Urine Pregnancy test</li>
<li>ECG (if myocardial infarction suspected)</li>
<li>Abdominal X-ray: Intestinal obstruction</li>
<li>Erect Chest X-ray: bowel perforation with air under diaphragm</li>
</ul>
<p><strong>Persistent Vomiting:</strong></p>
<ul>
<li>Upper gastro-intestinal endoscopy</li>
<li>Serum calcium level</li>
<li>CT scan of brain</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives</strong></p>
<ul>
<li>To identify and treat the underlying cause</li>
<li>To prevent dehydration and electrolyte imbalance</li>
<li>To maintain nutrition by ensuring adequate dietary intake during illness</li>
<li>To maintain personal hygiene</li>
<li>To eliminate infecting organisms where appropriate</li>
</ul>
<p><strong>Non-pharmacological treatment</strong></p>
<ul>
<li>Maintain adequate oral fluid intake (if tolerated)</li>
<li>Maintain adequate nutrition</li>
<li>Place naso-gastric tube when needed</li>
<li>Surgical intervention in suspected intestinal obstruction, peritonitis</li>
</ul>
<p><strong>Pharmacological treatment</strong></p>
<ol>
<li><strong>Suggested Anti-Emetics for use in Migraine</strong></li>
</ol>
<p>Evidence Rating: [B]</p>
<ul>
<li>Metoclopramide, oral/IV/IM,</li>
</ul>
<p><u>Adults</u></p>
<p>10 mg 8 hourly</p>
<p><strong>Or</strong></p>
<ul>
<li>Domperidone, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>10 mg, 8 hourly</p>
<p><u>Children</u></p>
<p>&gt;12 years (Body weight 2" 35 kg); 10 mg 8-12 hourly (max. 30 mg per day)</p>
<p>1 month-12 years (Body weight &lt;35 kg); 250 micrograms/kg 8-12 hourly (max. 750 microgram/kg per day)</p>
<p><strong>Or</strong></p>
<p><strong>Note 2-7</strong></p>
<p>Domperidone should be used at the lowest effective dose for the shortest possible duration. The maximum duration of treatment should not exceed 7 days).</p>
<p><strong>Or</strong></p>
<ul>
<li>Promethazine, IV/IM</li>
</ul>
<p><u>Adults</u></p>
<p>12.5-25 mg 6-8 hourly as needed (max. 100 mg in 24 hours)</p>
<p><strong>Or</strong></p>
<ul>
<li>Promethazine, oral,</li>
</ul>
<p><u>Children</u></p>
<p>2-12 years; 0.25-1 mg 6-8 hourly as needed (max. 25 mg per dose)</p>
<p>&lt; 2 years; Not recommended</p>
<ol>
<li><strong> Suggested Anti-Emetics for use in Vestibular Nausea and Vomiting</strong></li>
</ol>
<ul>
<li>Promethazine, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>20-25 mg 12 hourly</p>
<p><u>Children</u></p>
<p>2-12 years; 0.25-1 mg 6-8 hourly as needed (max. 25 mg per dose)</p>
<p>&lt; 2 years; Not recommended</p>
<p><strong>Or</strong></p>
<ul>
<li>Promethazine, IV/IM</li>
</ul>
<p><u>Adults</u></p>
<p>12.5-25 mg 6-8 hourly as needed (max. 100 mg in 24 hours)</p>
<p><strong>Or</strong></p>
<ul>
<li>Cyclizine, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>50 mg 8 hourly as needed</p>
<p><u>Children</u></p>
<p>6-12 years; 25 mg 8 hourly as needed (max. 75 mg in 24 hours)</p>
<p><strong>Or</strong></p>
<ul>
<li>Cinnarizine, IV/IM,</li>
</ul>
<p><u>Adults</u> and children &gt; 12 years</p>
<p>30 mg 8 hourly as needed</p>
<p><u>Children</u></p>
<p>5-12 years; 15 mg 8 hourly as needed</p>
<p>&lt; 5 years; not recommended</p>
<ol>
<li><strong> Suggested Anti-Emetics for use in Gastroenteritis</strong></li>
</ol>
<ul>
<li>Metoclopramide, oral/IV/IM,</li>
</ul>
<p><u>Adults</u></p>
<p>10 mg 8 hourly</p>
<p><strong>Or</strong></p>
<ul>
<li>Domperidone, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>10 mg, 8 hourly</p>
<p><u>Children</u></p>
<p>&gt;12 years (Body weight 2" 35 kg); 10 mg 8-12 hourly (max. 30 mg per day)</p>
<p>1 month-12 years (Body weight &lt; 35 kg); 250 micrograms/kg 8-12 hourly (max. 750 microgram/kg per day)</p>
<ol>
<li><strong> Suggested Anti-Emetics for use in Post-Operative Vomiting</strong></li>
</ol>
<ul>
<li>Metoclopramide, oral/IV/IM,</li>
</ul>
<p><u>Adults</u></p>
<p>10 mg 8 hourly</p>
<p><strong>O</strong><strong>r</strong></p>
<ul>
<li>Cyclizine, oral/IV/IM,</li>
</ul>
<p><u>Adults</u></p>
<p>50 mg 8 hourly as needed</p>
<p><u>Children</u></p>
<p>6-12 years; 25 mg 8 hourly as needed (max. 75 mg in 24 hours)</p>
<ol>
<li>E<strong>. Suggested Anti-Emetics for use in Chemotherapy-Induced Vomiting</strong></li>
</ol>
<ul>
<li>Ondansetron, IV,</li>
</ul>
<p><u>Adults</u></p>
<p>8 mg/ 0.15 mg/kg (pre-chemotherapy) infused over 15 minutes</p>
<p><u>Children</u></p>
<p>&gt;6 months; 0.15 mg/kg (pre-chemotherapy) infused over 15 minutes, then repeated 4 and 8 hours after first dose. (max is 16 mg/dose)</p>
<p><strong>Or</strong></p>
<ul>
<li>Odansetron, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>8 mg 12 hourly</p>
<p><u>Children</u></p>
<p>4-12 years; 4 mg 30 minutes before chemotherapy, then 4 mg 8 hourly for 24-48 hours as needed</p>
<p>&lt; 4 years; not recommended</p>
<p><strong>Or</strong></p>
<ul>
<li>Granisetron, IV,</li>
</ul>
<p><u>Adults</u></p>
<p>1mg/10 microgram/kg (30 minutes before Chemotherapy)</p>
<p><u>Children</u></p>
<p>2-16 years; same as adults</p>
<p>&lt;2 years; not recommended</p>
<p><strong>Or</strong></p>
<ul>
<li>Granisetron, oral,</li>
</ul>
<p><u>Adults</u></p>
<p>1mg 1 hour before chemotherapy, then 1 mg 12 hours after 1st dose</p>
<p><strong>Or</strong></p>
<p>2 mg 1 hour before chemotherapy</p>
<p><u>Children</u></p>
<p>Not recommended</p>
<p><strong>Or</strong></p>
<ul>
<li>Dexamethasone, oral/IV,</li>
</ul>
<p><u>Adults</u></p>
<p>8-12 mg before chemotherapy, then 8 mg 24 hourly from days 2-4</p>
<p><u>Children</u></p>
<p>Not recommended</p>
<p><strong>Or</strong></p>
<ul>
<li>Lorazepam, oral/IV,</li>
</ul>
<p><u>Adults</u></p>
<p>0.5-2 mg 6 hourly as required</p>
<p><u>Children</u></p>
<p>Consult a specialist</p>
<ol>
<li><strong> Suggested Anti-Emetics for use in Pregnancy</strong></li>
</ol>
<ul>
<li>Promethazine teoclate, oral, 1</li>
</ul>
<p>0-20 mg 8 hourly as needed Or</p>
<ul>
<li>Promethazine, IM,</li>
</ul>
<p>12.5-25 mg 8 hourly as needed</p>
<p><strong>Or</strong></p>
<ul>
<li>Metoclopramide, oral,</li>
</ul>
<p>10 mg 8 hourly</p>
<p><strong>Or</strong></p>
<ul>
<li>Metoclopramide, IV/IM, 10 mg 8 hourly as needed</li>
</ul>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>Refer all patients in whom vomiting persists or who show signs of progression in disease, patients with unexplained or persistent vomiting, and patients with suspected surgical cause of vomiting for specialist or surgical assessment and management<u>.</u></p>
<ol>
<li><strong>15</strong><strong>.</strong><strong> Hepatocellular Carcinoma</strong></li>
</ol>
<p>Hepatocellular Carcinoma (HCC) is a primary malignancy of the liver cell and must be differentiated from malignancies elsewhere that metastasize to the liver. Hepatocellular carcinoma occurs more commonly in men than in women and is often diagnosed several years after establishment of the initial causative condition. The disease has a poor prognosis resulting from metastatic or locally advanced disease. Complications include liver failure, variceal bleeding or tumour rupture with bleeding into the peritoneum. The tumour is often resistant to chemotherapy. Current strategies to prevent or treat hepatitis B and C infections and liver cirrhosis can potentially reduce the prevalence of HCC in the long term.</p>
<p><strong>CAUSES</strong></p>
<ul>
<li>Cirrhosis of the liver</li>
<li>Alcoholic liver disease</li>
<li>Chronic hepatitis B virus infection</li>
<li>Chronic hepatitis C virus infection</li>
<li>Chronic exposure to hepatic carcinogens e.g. aflatoxin</li>
</ul>
<p>SYMPTOMS</p>
<ul>
<li>Jaundice</li>
<li>Itching</li>
<li>Anorexia</li>
<li>Early satiety</li>
<li>Feeling of a mass in the upper abdomen</li>
<li>Right upper abdominal pain</li>
<li>Weight loss</li>
<li>Haematemesis</li>
<li>Abdominal distension</li>
<li>Bone pain</li>
<li>Dyspnoea</li>
</ul>
<p><strong>SIGNS</strong></p>
<ul>
<li>Jaundice</li>
<li>Cachexia</li>
<li>Hepatomegaly (irregular surface, multiple nodules, may be tender)</li>
<li>Ascites</li>
<li>Hepatic bruit</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<ul>
<li>FBC</li>
<li>LFTS</li>
<li>INR</li>
<li>Serum Alpha-Fetoprotein</li>
<li>Hepatitis B-Surface Antigen (HBsAg)</li>
<li>Hepatitis C Antibody (HCVab)</li>
<li>Chest X-Ray</li>
<li>Abdominal ultrasound scan</li>
<li>CT/MRI scan (if ultrasound inconclusive)</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives </strong></p>
<p><strong>Curative</strong></p>
<ul>
<li>To assess for potential resectability</li>
</ul>
<p><strong>Palliative</strong></p>
<ul>
<li>To relieve pain</li>
<li>To relieve discomfort from gross ascites</li>
<li>To prevent or treat hepatic encephalopathy (See section on 'Hepatic Encephalopathy')</li>
</ul>
<p><strong>Non-pharmacological treatment</strong></p>
<ul>
<li>Surgical resection of non-metastatic localised lesions</li>
<li>Paracentesis for tense ascites (See section on 'Ascites')</li>
<li>Supportive care (multi-vitamin supplements)</li>
</ul>
<p><strong>Pharmacological treatment</strong></p>
<ol>
<li><strong> Pain control in patients with Hepatocellular Carcinoma</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [B]</p>
<ul>
<li>Tramadol, oral, 50 mg 12 hourly (titrate further as tolerated to de- sired effect: maximum 300 mg daily)</li>
</ul>
<p><strong>Or</strong></p>
<ul>
<li>Morphine sulphate, oral, 5-10 mg 8-12 hourly</li>
</ul>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>Refer all patients with suspected HCC, especially those with small solitary lesion (&lt; 5 cm) who may be considered for percutaneous alcohol injection or surgical resection, to a specialist.</p>
<ol>
<li><strong>16</strong><strong>.</strong><strong> Drugs and the Liver</strong></li>
</ol>
<p>Drug-Induced Liver Injury (DILI) can occur following the use of a variety of either prescription or over-the-counter medications. A high index of suspicion is often necessary in establishing the diagnosis. Early recognition of drug toxicity is important to permit withdrawal of the offending drug, assessment of severity and monitoring for acute liver failure. Drug-induced liver injury can be dose-dependent or idiosyncratic.</p>
<p>The hallmark for the treatment of DILI is early withdrawal of the offending drug.</p>
<p><strong>CAUSES</strong></p>
<ul>
<li>Allopathic drugs (prescription, over-the-counter, anaesthetic agents, e.g. paracetamol, statins, isoniazid, halothane, amiodarone, azathioprine, carbamazepine, phenytoin, nevirapine, ketoconazole, flucloxacillin etc.)</li>
<li>Herbal preparations</li>
<li>Dietary supplements</li>
</ul>
<p><strong>SYMPTOMS</strong></p>
<ul>
<li>Asymptomatic</li>
<li>Right upper quadrant pain</li>
<li>Nausea</li>
<li>Anorexia</li>
<li>Malaise</li>
<li>Lethargy</li>
<li>Pruritus</li>
</ul>
<p><strong>SIGNS</strong></p>
<ul>
<li>0ccasionally none</li>
<li>Jaundice</li>
<li>Scratch marks</li>
<li>Bruising</li>
<li>Asterixis</li>
<li>Altered mental state</li>
<li>Signs of pre-existing chronic liver disease</li>
</ul>
<p><strong>INVESTIGATIONS</strong></p>
<ul>
<li>FBC</li>
<li>LFTS</li>
<li>BUE and Creatinine</li>
<li>Serum glucose</li>
<li>Urinalysis</li>
<li>Hepatitis screen (A, B, C, E) for exclusion</li>
<li>Abdominal ultrasound scan</li>
</ul>
<p><strong>TREATMENT</strong></p>
<p><strong>Treatment objectives</strong></p>
<ul>
<li>To identify and withdraw the offending agent</li>
<li>To report as adverse drug event to Food and Drugs Authority (FDA) promptly</li>
<li>To assess severity of liver disease</li>
<li>To administer antidote where applicable or feasible</li>
</ul>
<p><strong>Non-pharmacological treatment</strong></p>
<p>(See section on 'Hepatic Encephalopathy')</p>
<p><strong>Pharmacological treatment</strong></p>
<ol>
<li><strong> Drug-induced liver injury following paracetamol toxicity</strong></li>
</ol>
<p>1st Line Treatment</p>
<p>Evidence Rating: [A]</p>
<ul>
<li>N-Acetylcysteine</li>
</ul>
<p>(See section on 'Management algorithm for Acute Paracetamol Poisoning')</p>
<p><strong>REFERRAL CRITERIA</strong></p>
<p>All patients failing to improve or showing progression in liver injury despite withdrawal of offending drug should be referred to a specialist.</p>
<p><strong>Management algorithm for Acute Paracetamol Poisoning</strong></p>
<table>
<tbody>
<tr>
<td>
<p><strong>Box 2-1: Management algorithm for Acute Paracetamol Poisoning</strong></p>
</td>
</tr>
<tr>
<td>
<p>Clinical presentation</p>
</td>
</tr>
<tr>
<td>
<p>Nausea and vomiting are common early symptoms</p>
</td>
</tr>
<tr>
<td>
<p>Patients that subsequently develop hepatic injury and death may be asymptomatic for hours after an acute ingestion</p>
</td>
</tr>
<tr>
<td>
<p>Investigations</p>
</td>
</tr>
<tr>
<td>
<p>In all patients with suspected paracetamol toxicity, obtain the following:</p>
<p>Serum paracetamol concentration, baseline liver function tests (AST, ALT, total bilirubin), PT and INR, urea and electrolytes</p>
</td>
</tr>
<tr>
<td>
<p>In all patients with a suspected intentional overdose, obtain serum salicylate concentration, serum glucose, ECG, and pregnancy test in women of childbearing age</p>
</td>
</tr>
<tr>
<td>
<p>Treatment regimen</p>
</td>
</tr>
<tr>
<td>
<p>Secure airway, breathing, and circulation as necessary</p>
</td>
</tr>
<tr>
<td>
<p>Give activated charcoal (AC) 50 g to all adult patients presenting within 4 hours of ingestion, unless contraindicated; AC may be useful for co-ingestants beyond 4 hours</p>
</td>
</tr>
<tr>
<td>
<p>Treat with N-Acetylcysteine (NAC) If:</p>
</td>
</tr>
<tr>
<td>
<p>&bull; Serum paracetamol concentration drawn at 4 hours or more after a single acute ingestion is above the "treatment" line of the treatment nomogram for paracetamol poisoning</p>
</td>
</tr>
<tr>
<td>
<p>&bull; Serum paracetamol concentration is unavailable or will not return within 8 hours of time of ingestion and paracetamol ingestion is suspected</p>
</td>
</tr>
<tr>
<td>
<p>&bull; Time of ingestion is unknown and serum paracetamol level is greater than 10 microgram/ml (66 micromol/L)</p>
</td>
</tr>
<tr>
<td>
<p>&bull; There is evidence of any hepatotoxicity with a history of paracetamol ingestion</p>
</td>
</tr>
<tr>
<td>
<p>&bull; Patient reports or clinician suspects repeated excessive paracetamol ingestions, patient has risk factors for paracetamol-induced hepatotoxicity, and the serum paracetamol concentration is greater than 10 microgram/ml (66 micromol/L)</p>
</td>
</tr>
<tr>
<td>
<p>0ral Dosing 0f NAC:</p>
</td>
</tr>
<tr>
<td>
<p>&bull; 0ral dosing is acceptable for non-pregnant patients with a functional GI tract and no evidence of hepatotoxicity</p>
</td>
</tr>
<tr>
<td>
<p>&bull; Dose 140 mg/kg loading dose, followed by 17 doses of 70 mg/kg every 4 hours</p>
</td>
</tr>
<tr>
<td>
<p>&bull; If vomiting occurs within 1 hour of NAC dosing, a full NAC dose should be repeated as</p>
<p>rapidly as possible</p>
</td>
</tr>
<tr>
<td>
<p>&bull; Therapy may be terminated by 24 to 36 hours after ingestion if the paracetamol level is below 10 micrograms/ml, and the patient does not develop evidence of hepatotox- icity and remains clinically well</p>
</td>
</tr>
<tr>
<td>
<p>Intravenous (IV) dosing of NAC:</p>
</td>
</tr>
<tr>
<td>
<p>&bull; In patients with no biochemical evidence of liver failure (i.e., those with INR &lt;2), use 21 hour IV protocol: 150 mg/kg loading dose over 60 minutes, followed by 50 mg/kg infused over 4 hours, with the final 100 mg/kg infused over the remaining 16 hours</p>
</td>
</tr>
<tr>
<td>
<p>&bull; In patients with biochemical evidence of liver failure (i.e., those with INR &gt;2), administer the 21 hour IV protocol (150 mg/kg loading dose over 60 minutes, followed by 50 mg/kg infused over 4 hours, followed by 100 mg/kg infused over the next 16 hours) followed by a continuous IV NAC infusion at 6.25 mg/kg per hour until INR is &lt; 2</p>
</td>
</tr>
<tr>
<td>
<p>&bull; IV dosing is acceptable in all cases of paracetamol toxicity, but should be used instead of oral dosing in patients unable to tolerate oral NAC (e.g., intractable vomiting), patients with a medical condition precluding administration of oral NAC (eg, corrosive ingestion, GI bleed), patients with significant hepatotoxicity (INR &gt;2), and pregnant patients</p>
</td>
</tr>
<tr>
<td>
<p>Antiemetic therapy:</p>
</td>
</tr>
<tr>
<td>
<p>&bull; May give IV metoclopramide 10 mg 8 hourly</p>
</td>
</tr>
</tbody>
</table>